IGEA Pharma N.V. Stock

IGPH

NL0012768675

Medical Equipment, Supplies & Distribution

Latest news : IGEA Pharma N.V.

23-12-19	Igea Pharma to Delist from SIX Swiss Exchange	MT
23-11-06	Swiss Market Index Flat Amid Expected Labor Market Growth	MT
23-11-06	Appeals Board Upholds Decision to Delist IGEA Pharma from SIX Swiss Exchange on Questionable Solvency	MT
23-10-03	IGEA Pharma to Merge Divisions With RBCARE2023	MT
23-10-02	IGEA Pharma Swings to H1 Profit	MT
23-09-30	IGEA Pharma N.V. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
23-08-31	IGEA Pharma Appeals Delisting Notice from SIX Swiss Exchange	MT
23-08-03	IGEA Pharma to Delist from SIX Swiss Exchange in November	MT
23-07-30	IGEA Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-06-01	Achiko, IGEA, Talenthouse Shares Suspended from Trading on SIX Swiss Exchange	MT
23-06-01	IGEA Pharma Seeks Deadline Extension for FY22 Annual Report Publication	MT
23-05-30	IGEA Pharma to Divest Industrial Process Business in Refocusing Move	MT
23-04-13	IGEA Pharma Receives Fine for Breach of Listing Rules	MT

More news

Press Releases: IGEA Pharma N.V.

24-03-06	IGEA Pharma N : ForHealthy NV to effect a reverse share split	PU
23-11-13	IGEA Pharma N.V.: IGEA announces annual General Meeting Resolutions	EQ
23-10-09	IGEA Pharma N.V.: IGEA to update on RBCARE business combination	EQ
23-10-03	IGEA Pharma N.V.: IGEA and RBCARE2023 signed to combine their businesses	EQ
23-09-30	IGEA Pharma N.V.: IGEA discloses its half-year figures 2023	EQ

More press releases

News in other languages: IGEA Pharma N.V.

23-12-19	Igea formellement décoté de la Bourse suisse
23-12-19	IGEA Pharma scheitert mit Beschwerde - Aktie wird dekotiert
23-11-06	Igea Pharma: recours contre la décotation rejeté
23-11-06	IGEA-Rekurs gegen Dekotierung wird von SIX-Beschwerdeinstanz abgewiesen
23-10-10	Igea: perspectives précisées pour Rbcare2023

More news

Managers and Directors: IGEA Pharma N.V.

Manager	Title	Age	Since
Pierpaolo Cerani CEO	Chief Executive Officer	-	2023-04-23
Anna Babuder COO	Chief Operating Officer	-	-
Gianfranco Liguri CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Federico Bazzoni BRD	Director/Board Member	66	2018-12-13
Angelo Strazzella CHM	Chairman	-	2023-04-23
Pellegrino De Santis BRD	Director/Board Member	-	2023-04-23

More insiders

Diagnostic & Testing Substances

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
IGEA PHARMA N.V.	+200.00%	+200.00%	-	-	604K
GUARDANT HEALTH, INC.	+3.73%	+9.25%	+129.61%	+306.71%	12.69B
BIOMÉRIEUX	-0.63%	-0.84%	-38.55%	-27.54%	9.87B
LANTHEUS HOLDINGS, INC.	+2.26%	+8.84%	+15.69%	-1.86%	6.05B
CARIS LIFE SCIENCES, INC.	-18.60%	-12.56%	-	-	4.57B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+0.49%	-1.70%	-9.31%	-8.84%	5.48B
ANDON HEALTH CO., LTD.	-2.77%	+3.58%	+101.46%	+85.28%	4.68B
DIASORIN S.P.A.	-1.62%	+8.93%	-34.71%	-38.07%	3.94B
10X GENOMICS, INC.	-3.66%	-3.70%	+150.29%	-60.35%	2.79B
AUTOBIO DIAGNOSTICS CO., LTD.	+1.73%	+1.82%	-12.74%	-37.98%	2.87B
Average	+18.09%	+1.11%	+37.72%	+27.17%	5.88B
Weighted average by Cap.	-0.98%	+2.41%	+41.94%	+73.03%

See all sector performances

IGEA Pharma NV is a biopharmaceutical company based in the Netherlands. The Company focuses on research and development of biomedical solutions for the prevention of diabetes and Alzheimer's disease. Its offering portfolio includes medical testing devices and dietary supplements. The Company develops ALZ-1 Test, a blood test to measure and control level of free copper, also known as Free Copper II or Non-Ceruloplasmin Copper in the bloodstream, which is a major recognized modifiable risk factor for the Alzheimer's disease. The Company offers its services in the Netherlands.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company